COMPANY INFO
DeepCure, founded in 2018 by Joseph Jacobson, Kfir Schreiber, and Thrasyvoulos Karydis, is a private drug discovery company with approximately 49 employees headquartered in Boston, MA. The company develops a drug discovery platform that combines deep learning algorithms, cloud computing, and a proprietary chemistry database to accelerate the creation of novel small molecule therapies for immune diseases, aiming to improve pre-clinical drug development and deliver better treatments for patients. Their website is deepcure.com and they operate primarily in the drug discovery industry. (PitchBook, Tracxn)
DeepCure, founded in 2018 by Joseph Jacobson, Kfir Schreiber, and Thrasyvoulos Karydis, is an innovative drug discovery company headquartered in Boston, MA. Operating within the drug discovery industry, DeepCure specializes in developing a proprietary platform that leverages deep learning, advanced cloud computing, and a vast chemistry database to accelerate the development of novel small molecule therapies. Their technology is designed to revolutionize pre-clinical drug development for immune diseases, aiming to deliver more effective treatments to patients worldwide. With approximately 49 employees and a global presence including offices in the United States, Israel, Denmark, and Greece, DeepCure is at the forefront of AI-driven pharmaceutical research.
Over the course of its growth, DeepCure funding has amounted to approximately $71.4 million, raised through 2 major rounds. The company’s funding strategy has focused on advancing its AI-driven drug discovery platform and supporting crucial stages in pre-clinical drug development. Noteworthy milestones in DeepCure funding rounds include both Series A and Series A-1 financings, which attracted high-profile venture capital and strategic investors. The capital raised has enabled the company to further its mission in developing next-generation therapies, enhance automation, and expand its portfolio of drug programs in immunology and inflammation.
This Series A-1 financing round was dedicated to accelerating DeepCure’s programs in immunology and inflammation. The funds are being used to further expand the company’s capabilities in AI and automation, advancing small molecule drug discovery and scaling up pre-clinical R&D efforts.
DeepCure’s Series A round supported the advancement of its pre-clinical drug development pipeline and expansion of its AI-driven discovery platform. The capital raised laid the groundwork for new therapeutic research and further established DeepCure as a leader in next-generation drug discovery.
IAG Capital Partners led DeepCure’s Series A-1 financing round in 2024. As an active investor in advanced biotech and healthcare innovation, IAG Capital Partners plays a key role in enabling DeepCure’s expansion into new therapeutic areas and technological advancements.
Morningside Ventures led the Series A round in 2021 and has been instrumental in fueling DeepCure’s early-stage development. Known for its investments in life sciences, Morningside’s involvement ensures strategic guidance and substantial financial resources.
TLV Partners participated as a lead investor in the Series A round. With a strong track record in funding high-impact technology and healthcare startups, TLV Partners supports DeepCure’s growth through capital, connections, and industry expertise.
E14 Fund is an MIT-affiliated VC fund that invests in companies founded by MIT alumni and faculty. Their partnership underscores DeepCure’s strong academic and technical foundation, supporting ongoing innovation.
5Y Capital is a globally recognized venture capital firm, providing strategic investment that helps DeepCure scale its platform and enter new markets.
Benon Group’s participation aligns with DeepCure’s mission to revolutionize drug discovery, providing both financial resources and strategic insight.
Morningside Group, associated with Morningside Ventures, adds further backing and network support to DeepCure’s ongoing development initiatives.
Websets is a powerful natural language search and data enrichment tool that helps you discover comprehensive funding information for any company. Whether you're researching DeepCure funding rounds or exploring investment data for other companies, Websets provides detailed insights into funding history, investors, and financial milestones.
With Websets, you can access detailed funding profiles, investor information, and financial data through intuitive natural language queries. Sign up now to enhance your funding research capabilities.